Peters Helps Advance Bill to Lower Prescription Drug Prices From Committee

November 8, 2019 by Dan McCue
Peters Helps Advance Bill to Lower Prescription Drug Prices From Committee

WASHINGTON – Rep. Scott Peters, D-Calif., helped advance H.R. 3, the Lower Drug Costs Now Act, joining the majority of his colleagues on the Energy and Commerce Committee in voting to send the measure on to the full House.

The measure, introduced in the House on Sept. 19, establishes several programs and requirements relating to lowering the prices of prescription drugs.

“No one in a nation as great as ours should have to choose between groceries and the medicine they need to survive and lead healthy lives,” Rep. Peters said after the 30-22 vote.

Calling the bill “a major overhaul of the drug pricing landscape” Peters explained that one provision of the bill will allow the federal government to negotiate drug prices with pharmaceutical companies in Medicare to lower drug costs for seniors and people living with chronic disease, among others.

Despite his support of the bill, Peters acknowledged it is not perfect.

“San Diego is home to tens of thousands of scientists, entrepreneurs, academics, and researchers who make drugs to treat diabetes, cystic fibrosis, Parkinson’s, and even cancer,” he said. “As we work to lower drug costs, we must preserve the unique innovation ecosystem in San Diego and the United States more broadly that continues to deliver breakthrough therapies and cures for our constituents.

“We want and need a market that continues to produce new drugs and therapies that can cure deadly and chronic disease. I made clear my concerns with parts of this bill, and received commitments from Chairman Pallone to work with me to address the parts I think must be improved,” Peters said.

Rep. Frank Pallone Jr., D-N.J., is chairman of the House Energy and Commerce Committee.

H.R. 3 includes three main mechanisms to help lower drug costs:

First, the bill enables the Secretary of Health and Human Services (HHS) to negotiate the price that Medicare pays for at least 25 of the highest-cost drugs without at least two competitors on the market each year.

The bill establishes an international reference price to inform the Secretary’s negotiation, and caps the price paid by the federal government for a drug at 120% of the average price paid by Australia, the United Kingdom, Japan, Canada, Germany, and France.

For drugs that are new to the market or which are not available in those other countries, the Secretary would have authority to negotiate a 15% discount on the list price. If a drug manufacturer refuses to negotiate the price of a drug with the Secretary, the Secretary is authorized to institute an excise tax of 95% of revenue from the non-negotiated drug.

Second, the bill establishes an inflationary rebate program in Medicare Parts B and D that would tie annual price increases for either branded or generic drugs (including biologics and biosimilars) to inflation.

If a manufacturer increases prices in a given year above the rate of inflation, the federal government requires the manufacturer to rebate the difference between the price increase and the rate of inflation to the federal government.

Finally, the bill reimagines the cost-sharing structure for the Medicare Part D benefit. In doing so, Part D enrollees would spend a maximum of $2,000 out of pocket on drugs each year, and plan providers and drug manufacturers would cover more of the costs above $2,000 than they currently do.

After the committee vote, Rep. Pallone said, “We are one step closer to finally empowering the federal government to negotiate lower prescription drug prices for the American people.” 

“The Lower Drug Costs Now Act levels the playing field by ensuring that Americans are not forced to pay three, four or ten times more than people in other countries for the same drugs.   This transformative legislation will also save taxpayers hundreds of billions of dollars that we can reinvest in the search for new cures and treatments and strengthening our health care system,” he said.

A+
a-
  • Drug Prices
  • Energy and Commerce Committee
  • Scott Peters
  • In The News

    Health

    Voting

    Prescription Drugs

    Biden and Harris Team Up for Health Care Event in North Carolina

    WASHINGTON (AP) — President Joe Biden and Vice President Kamala Harris will promote their health care agenda on Tuesday in... Read More

    WASHINGTON (AP) — President Joe Biden and Vice President Kamala Harris will promote their health care agenda on Tuesday in North Carolina, a battleground state that Democrats hope to flip in their favor after falling short to Donald Trump in the last two presidential elections. Fourteen... Read More

    March 13, 2024
    by Dan McCue
    FDA Believed Poised to Approve First Med for a Serious Liver Disease

    WASHINGTON — The Food and Drug Administration appears poised to approve the first medicine developed specifically to treat the serious... Read More

    WASHINGTON — The Food and Drug Administration appears poised to approve the first medicine developed specifically to treat the serious liver disease known as MASH later this week.  Metabolic dysfunction-associated steatohepatitis -- formerly known as nonalcoholic steatohepatitis — is often associated with obesity. In patients who... Read More

    March 6, 2024
    by Dan McCue
    Health Care, Drug Prices to Be Cornerstone of State of the Union

    WASHINGTON — President Joe Biden’s plans to do more to lower prescription drug prices and ensure the nation’s health care... Read More

    WASHINGTON — President Joe Biden’s plans to do more to lower prescription drug prices and ensure the nation’s health care system works better for more Americans will be the centerpiece of his State of the Union address, the White House revealed Wednesday. In a conference call... Read More

    March 4, 2024
    by Dan McCue
    Judge Rules Against Drugmaker in Price Negotiation Lawsuit

    WILMINGTON, Del. — A federal judge in Delaware ruled against the pharmaceutical and biotech company AstraZeneca last Friday in a... Read More

    WILMINGTON, Del. — A federal judge in Delaware ruled against the pharmaceutical and biotech company AstraZeneca last Friday in a case challenging the constitutionality of Medicare’s new drug negotiation program. The case is one of several filed by the pharmaceutical industry and its allies and the... Read More

    March 1, 2024
    by Dan McCue
    CVS, Walgreens to Begin Selling Abortion Pills Later This Month

    WASHINGTON — The nation’s two largest pharmacy chains will start dispensing the abortion pill mifepristone in select states later this... Read More

    WASHINGTON — The nation’s two largest pharmacy chains will start dispensing the abortion pill mifepristone in select states later this month, just weeks before the Supreme Court is set to hear a case that could lead to its removal from the market. The decision by both... Read More

    February 22, 2024
    by Dan McCue
    House Democrats Launch Inquiry Into Nationwide Drug Shortages

    WASHINGTON — Democrats on the House Committee on Oversight and Accountability are pressing some of the nation's largest drug manufacturers... Read More

    WASHINGTON — Democrats on the House Committee on Oversight and Accountability are pressing some of the nation's largest drug manufacturers for answers on why there are still intermittent and repeated shortages of cancer meds and other drugs. Led by Rep. Jamie Raskin, D-Md., the ranking member... Read More

    News From The Well
    scroll top